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A B S T R A C T
A 32 base pair deletion in the C-C chemokine receptor type gene (CCR5-Δ32), the main Human Immunodeficiency Virus (HIV) co-receptor results in a non-functional
protein. Individuals homozygous for the CCR5-Δ32 mutation are resistant to HIV infection. Here we report the generation, from pro-erythroblast enriched Peripheral
Blood Mononuclear Cells (PBMCs) from a naturally occurring CCR5-Δ32/Δ32 individual, of the fully characterized iPSC line IMEDEAi008-A. The new line has normal
karyotype, carry the Δ32 mutation in homozygosity, is free of plasmid integrations, express high levels of pluripotency markers and can differentiate into all three
germ layers.
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Type of cell line iPSCs
Origin Human
Additional origin info Age: N/A
Sex: Female
Ethnicity if known: Caucasian
Cell Source Original cell type: Peripheral Blood Mononuclear Cell
(PBMC)





Type of Modification N/A
Associated disease N/A
Gene/locus N/A
Method of modification N/A












Registered in the Human Pluripotent Stem Cell Registry
(https://hpscreg.eu).
Ethical approval The donor blood sample was provided by the Biobank of
Instituto de Investigaciones Sanitarias Illes Balears with
the approval of the Comité Etico de Investigacion Clínica
de las Ilslas Baleares (Spain). Approval number IB3422/
17PI.
1. Resource utility
IMEDEAi008-A has been produced by reprogramming a pro-ery-
throblast enriched population obtained from PBMCs. Due to the dif-
ferences in reprogramming technology and the fact that the epigenetic
signature and gene expression pattern in progenitor blood cells like pro-
erythroblast is closer to ESC than those of fibroblasts, IMEDEAi008A
could be a good complement to the CCR5-Δ32/Δ32 fibroblast-derived
iPSC lines recently described (Chen et al., 2019). In addition, its cellular
origin could make it easier to use in hematopoietic differentiation than
the fibroblast-derived iPSCs. This line represents a non-invasive, easy
accessible and unlimited source of CCR5-Δ32/Δ32 iPSCs that could be
differentiated to study the multiple roles of CCR5 in infectious diseases
(Klein, 2008), or its potential use in cell therapy approaches for the
treatment of AIDS.
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2. Resource details
To date, there is no cure for HIV infection. Anti-retroviral therapies
can control viral replication but not eradicate the virus, which results,
at best, in the chronification of the disease. To solve the situation,
several cell and gene-based therapies have been tried. Genetic mod-
ification of autologous HSCs and T-cells is laborious, time-consuming
and entails the risks commonly associated to genetic engineering. On
the other hand, although the efficiency of allogeneic CCR5-Δ32/Δ32
HSCs transplantation has been demonstrated, the scarcity of homo-
zygous donors constitutes an important limitation for its wide appli-
cation.
One possible way out of the problem could be the use of iPSCs de-
rived from naturally occurring CCR5-Δ32/Δ32 donors as an unlimited
source of material for the production of HSCs.
IMEDEAi008-A was obtained by OriP/EBNA (Epstein-Barr nuclear
antigen-1) episomal plasmid reprogramming (Okita et al., 2011)
(OCT3/4, SOX2, KLF4, L-MYC, LIN28, BCL-xL and shp53) of natural
CCR5-Δ32/Δ32 pro-erythroblast enriched PBMC population. Pro-ery-
throblast (CD36+/CD71+) expansion (Supplementary Fig. S1) during
7 days of culture (Supplementary Fig. S2) before reprogramming in-
creased several folds their number and at the same time reduced
drastically the percentage of cells with V(D)J genetic rearrangements.
The resulting iPSC line showed morphology (Fig. 1A) and growth be-
havior typical of human Embryonic Stem Cells (hESC) indicating that
CCR5 is not required during reprogramming. The new line also dis-
played normal female karyotype (46, XX) (Fig. 1B). In addition, after
PCR analysis using specific primers (Table 2) that amplify the common
element in all plasmids: OriP/EBNA, it was confirmed the absence of
plasmid integration (Fig. 1G). Short tandem repeat (STR) analysis
(Table 1, data not shown) indicated a 100% match with parental
PBMCs. DNA sequencing was used to identify the delta 32 (Δ32) dele-
tion in CCR5 (Fig. 1C). Regarding stemness, immunocytochemical
analysis demonstrated the expression of the pluripotency-associated
markers: SOX2, OCT3/4, TRA 1-60 and NANOG (Fig. 1D), while SSEA-4
and TRA-1-81 expression was confirmed by quantitative flow cytometry
(Fig. 1E). Finally, directed differentiation into all three germ layers
proved the differentiation potential of the line. The expression of spe-
cific markers for ectoderm, mesoderm and endoderm in the differ-
entiated cells was analyzed by immunocytochemistry (Fig. 1F). Absence
of mycoplasma was also assessed (Supplementary Fig. S3).
In summary, IMEDEAi008-A is a very interesting CCR5-Δ32 homo-
zygous iPSC line with possible applications in the study of HIV infection
pathophysiology as well as in the development of HSC-based allogeneic
cell therapies.
3. Materials and methods
3.1. iPSCs derivation and expansion
Peripheral Blood Mononuclear Cells (PBMCs) were isolated by ficoll
from a natural homozygous CCR5-Δ32 donor peripheral blood sample.
PBMCs were cultured in a pro-erythroblast serum-free specific media
(1:1 IMDM/Ham’s F12 supplemented with: 1% ITS-X, 1% Chemically
Defined Lipid Concentrate, 1% Glutamax, 0.025 g/L L-Ascorbic Acid,
5 g/L BSA, 100 ng/ml SCF, 10 ng/ml IL3, 2U/ml EPO, 40 ng/ml IGF-1,
1 µM Dexamethasone and 100 µg/ml Holo-transferrin). After 7 days of
culture, 8 × 106 cells were nucleofected with four OriP/EBNA1-based
episomal plasmids: 2 μg of pCXLE-hOCT3/4-shp53, 2 μg of pCXLE-hSK
and 2 μg of pCXLE-hUL (Vallejo-Diez et al., 2019) in addition to 2 μg of
GBX. Cells were cultured on one p12 well and pro-erythroblast com-
plete medium supplemented with 10 µM Rock Inhibitor Y-27632 for
48 h. Reprogrammed cells were counted and 5 × 105 cells/well were
seeded on p6 well plates coated with MEF-CD1 feeders. Culturing media
was gradually changed from pro-erythroblast to hiPS medium:
Knockout DMEM (Invitrogen) supplemented with 20% Knockout Serum
Replacement (Invitrogen), 2 mM GlutaMAX, 1% NEAA, 50U/ml Peni-
cillin, 50 mg/ml Streptomycin, 0,1m Mercaptoethanol and 8 ng/ml
bFGF.and. From day 6 after reprogramming, NaB (0.5 mM) and Vitamin
C (50 µg/ml) were added to the media.
After 18 days in culture, iPS colonies were manually isolated and
grown on MEF CD1 until passage 3 when cells where seeded on human
Fig. 1. Characterization of a novel human iPSC line IMEDEAi008-A. (A) Phase contrast image of the iPSC line growing on passage 13 on a feeder-coated plate (scale
bar = 100 μm). (B) Normal female karyotype of IMEDEAi008-A after G band analysis. (C) Sequencing of the CCR5 gene in primary PBMCs and IMEDEAi008-A to
confirm the presence of the 32 bp deletion. (D) Immunofluorescence assay demonstrating the pluripotency phenotype of the line by the expression of SOX2, OCT3/4,
TRA 1-60 and NANOG. (E) Flow cytometry analysis of SSEA4 and TRA 1-81 expression. (F) Immunofluorescence assay showing that after 10 days of directed
differentiation IMEDEAi008-A cells express specific markers of ectoderm, mesoderm and endoderm. (G) The absence of episomal plasmid integration (EBNA) in
IMEDEAi008-A was checked by PCR. GAPDH, housekeeping control for PCR analysis.
Table 1
Characterization and validation.
Classification Test Result Data
Morphology Photography Normal appearance of packed iPS colonies. Scale bars: 100 μm Fig. 1 panel A
Phenotype Qualitative analysis by
Immunocytochemistry
The cell line expressed the pluripotency markers: SOX2, OCT3/4, TRA-1-60
and NANOG.
Fig. 1 panel D
Quantitative analysis by Flow
Cytometry
The cell line expressed high levels of the pluripotency markers SSEA-4 and
TRA-1-81
Fig. 1. Panel E
Genotype Karyotype (G-banding) and resolution IMEDEAi008-A: 46, XX
Resolution 450–500
Fig. 1. Panel B
Identity Microsatellite PCR analysis
STR analysis
Not performed
The STR profiles of cell line matched 100% with that of the parental PBMCs





Sequencing Homozygous delta32 deletion of CCR5 (CCR5-Δ32/Δ32) Fig. 1. Panel C
Microbiology and virology Mycoplasma Mycoplasma testing by PCR using MycoSPY Kit (Biontex). Submitted in archive
with journal
Differentiation potential Directed differentiation The cell line differentiated into the three germ layers including ectoderm
(Nestin, Pax6 and TUJ-1), mesoderm (GATA-4, α-SMA and Vimentin) and
endoderm (Sox17, AFP and FoxA2).
Fig. 1. Panel F
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HFF1-W3R feeders. Rock Inhibitor Y-27632 was used at 10 μM during
the passages. Cells were cultured at 37 °C and 5% CO2 in a humidified
incubator.
3.2. Karyotype analysis
G-banded metaphases analysis was carried out by Biobanco del
Sistema Sanitario Público de Andalucía (Granada, Spain).
3.3. Reprogramming plasmid integration analysis
PCR analysis was used to detect a common element of all the re-
programming plasmids: OriP/EBNA-1. Amplification reactions were
carried according to standard protocols with WonderTaq (Euroclone).
3.4. STR analysis and sequencing
After DNA isolation, CCR5 was amplified by PCR using EuroTaq
(Euroclone) and primers detailed in Table 2. Amplicons were sequenced
by SECUGEN S.L (Madrid) using a 96-capillary DNA analyser Abi 3730.
STR analysis was performed by the Genomics Core facility at the
Instituto de Investigaciones Biomédicas (IIBM, Madrid).
3.5. In vitro directed differentiation
Ectoderm, mesoderm and endoderm differentiation was performed
as described previously (Vallejo-Diez et al., 2019). After 10 days of
culture cells were fixed in PFA 4% for immunocytochemistry.
3.6. Immunofluorescence staining
Undifferentiated iPSCs (for pluripotency markers assays) and dif-
ferentiated cells (for differentiation potential assays) were washed with
PBS, fixed for 20 min, washed again with PBS and permeabilized with
0,2% Triton X-100 and 100 mM glycine in PBS for 30 min at room
temperature (RT). To block non-specific binding sites, PBS 5% BSA was
added an incubated for 60 min at RT. Primary antibodies incubation
was done overnight at 4 °C in PBS 2% BSA. After three washes with PBS,
cells were incubated with fluorescence-conjugated secondary anti-
bodies in PBS 2% BSA for 60 min at RT and darkness. The antibodies
used are described in Table 2. After washing with PBS, cells were
stained with DAPI for 5 min at RT in darkness.
Table 2
Reagent details.
Antibodies used for immunocytochemistry
Antibody Dilution Company Cat # and RRID
Pluripotency Markers Mouse anti-OCT4 1:50 Santa Cruz Biotech; sc-5279; RRID:AB_628051
Rabbit anti-NANOG 1:200 Cell Signaling; D73G4; RRID:AB_10559205
Mouse anti-SOX2 1:100 R and D Systems; MAB2018;
Mouse anti-TRA-1-60 1:100 RRID:AB_177629
Millipore; MAB4360; RRID:AB_2119183
Differentiation Markers Rabbit anti-Nestin 1:500 Sigma-Aldrich; N5413; RRID:AB_1841032
Rabbit anti-TUJ-1 1:500 Covance; MRB-435P-100; RRID:AB_663339
Mouse anti-Pax6 1:100 DSHB pax6, RRID:AB_528427
Mouse anti-GATA-4 1:300 Santa Cruz Biotech; sc-25310; RRID:AB_627667
Mouse anti-Vimentin 1:100 Abcam; ab80667
RRID:AB_1603290
Mouse anti-α-SMA 1:200 Sigma-Aldrich; A2547
RRID:AB_476701
Goat anti-SOX-17 1:100 R&D Systems; AF1924; RRID:AB_355060
Rabbit anti-AFP 1:200 Dako; A0008; RRID:AB_2650473
Rabbit anti-FoxA2 1:400 Cell Signaling; 8186
RRID:AB_10891055
Secondary antibodies Alexa Fluor 555 Donkey Anti-Rabbit IgG 1:500 Invitrogen; A-31572; RRID:AB_162543
Alexa Fluor 555 Donkey Anti-Mouse IgG 1:500 Invitrogen; A-315700
RRID:AB_2536180
Alexa Fluor 488 Donkey Anti-Mouse IgG 1:500 Invitrogen; A-21202; RRID:AB_141607
Alexa Fluor 555 Donkey Anti-Goat IgG (tiene q sere n 555) 1:500 Invitrogen; A-21432, RRID: AB_2535853
Alexa Fluor 488 Donkey Anti-Rabbit IgG 1:500 Invitrogen; A-21206
RRID:AB_141708
Antibodies used for Flow Cytometry
Antibody Vol. per test Company Cat # and RRID
Pluripotency Markers Mouse Anti TRA-1-81, APC 20 μl BD Biosciences; 560793;
RRID:AB_10550550
Mouse Anti SSEA-4, PE 20μl BD Biosciences; 560128
RRID:AB_1645533
Mouse IgM, k Isotype Control, APC 1 μl BD Biosciences; 560806;
RRID:AB_2034030
Mouse IgG3, k Isotype Control PE 1 μl BD Biosciences; 559926
RRID:AB_10050453
Primers
Target Forward/Reverse primer (5′-3′)
Episomal Plasmids Integration PCR EBNA ATCGTCAAAGCTGCACACAG/CCCAGGAGTCCCAGTAGTCA
House-Keeping Genes (PCR) GAPDH GCACCGTCAAGGCTGAGAAC/AGGGATCTCGCTCCTGGAA
Sequencing CCR5 TTAAAAGCCAGGACGGTCAC/TGTAGGGAGCCCAGAAGAGA
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3.7. Flow cytometry analysis of pluripotency marker
Cells were detached with Tryple and incubated 45 min and 4 °C with
conjugated antibodies (Table 2) against cells surface markers TRA-1-81
and SSEA-4. The corresponding isotype antibodies were used as con-
trols. Influx Cell Sorter and BD 1.0.0.650 Software were used for the
cytometry analysis.
3.8. Mycoplasma detection
Mycoplasma testing was carried out using the MycoSPY
Mycoplasma PCR detection kit (Biontex), which detects a wide range of
bacteria from the Mollicutes class. An Internal Control template was
included to discard the presence of PCR inhibitors and rule out false
positive results.
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